Company intelligence / Profile preview

Scioderm

Durham, North Carolina, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 3

Overview

Scioderm developed SD‑101 (Zorblisa), a topical therapy for Epidermolysis Bullosa. In an open-label Phase 2 study, SD‑101 achieved complete closure of 88% of target chronic lesions within one month and a 57% reduction in body surface area coverage of lesions after three months. The drug received FDA Breakthrough Therapy designation and Orphan Drug status from both the FDA and EMA. At the time of its acquisition by Amicus Therapeutics in September 2015, SD‑101 was enrolling patients in a pivotal Phase 3 trial as the first-ever drug candidate to reach this stage for EB[1][3][5].

Therapeutic areas: Dermatology
Modalities: Small moleculeTopical cream (as a delivery modality)
Industry: Biotech

Drug pipeline

1 asset

SD-101

Phase 3

Indications: Epidermolysis bullosa

Partnerships

No major external pharma partnerships disclosed prior to or during acquisition.

Beyond the preview

Go deeper on Scioderm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scioderm.

Explore the full profile